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Bioscience Division, Los Alamos National Laboratory, Los Alamos, NM, USA
Genome science and technologies are transforming life sciences globally in many ways
and becoming a highly desirable area for international collaboration to strengthen global
health. TheGenome Science Program at the Los AlamosNational Laboratory is leveraging
a long history of expertise in genomics research to assist multiple partner nations
in advancing their genomics and bioinformatics capabilities. The capability develop-
ment objectives focus on providing a molecular genomics-based scientific approach
for pathogen detection, characterization, and biosurveillance applications. The general
approaches include introduction of basic principles in genomics technologies, training
on laboratory methodologies and bioinformatic analysis of resulting data, procurement,
and installation of next-generation sequencing instruments, establishing bioinformatics
software capabilities, and exploring collaborative applications of the genomics capabilities
in public health. Genome centers have been established with public health and research
institutions in the Republic of Georgia, Kingdom of Jordan, Uganda, and Gabon;
broader collaborations in genomics applications have also been developed with research
institutions in many other countries.
Keywords: genomics, next-generation sequencing, international collaboration, pathogen detection, global health,
one health, bioinformatics, capability development
BACKGROUND AND INTRODUCTION
In early 2010, the prominent general scientific society in the US, the American Association for the
Advancement of Science (AAAS), recognized that international scientific collaboration is critical
to addressing complex societal challenges in health, agriculture, environment, energy, and global
security, and organized a series of four conferences under the common theme of “International
Engagement: Responsible Bioscience for a Safe and Secure Society.” In a period of 2 years, these
conferences examined the critical issues and explored the potentially sustainable approaches for
collaboration between the scientists in the US and other countries, with the focus on the broader
Middle Eastern and North African region. The major themes resulting from these conferences
revealed a clear desire for cooperative research and development with responsible scientific practice
and progressive action to enhance the infectious disease surveillance under the One Health concept
(1). Although the AAAS conference series was focused on one region, the concept derived from the
meeting and approaches that can be taken are undoubtedly applicable to many other countries and
regions. Successful and sustainable partnerships that build upon mutual interests, complementary
capabilities, and supporting infrastructure are essential to addressing complex global challenges,
such as approaching the One Health concept. Scientists with interest and resources to initiate and
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maintain partnerships with colleagues in other countries, andwho
are able to overcome existing barriers to collaboration, serve as the
foundation for successful international cooperation.
Reducing global health security risk from the spread of dan-
gerous infectious diseases, whether natural or manmade, is a
shared priority among the worldwide public health communities.
It has also become an overarching objective for international
cooperative biothreat reduction and scientific engagement efforts.
Engaging with and empowering infectious disease detection and
surveillance capabilities in the partner countries enable a global
network to reduce risk and enhance compliancewith international
guidelines, such as the International Health Regulations (from the
World Health Organization in 2005) and those by World Organi-
zation for Animal Health (OIE). Extensive international collab-
orations have been developed to address global health security
challenges, with activities, such as bioethics discussion, responsive
scientific conduct, biorisk management, and field epidemiology,
which have resulted in a positive global impact.
A well-suited scientific approach complementary to the
above activities is next-generation sequencing-enabled genomics
research for global health security applications. Genomics is a
relatively new scientific discipline but is fundamental to many
approaches to health security. Aided by highly automated Next-
Generation DNA Sequencing (NGS) technologies, the field has
been advancing dramatically, both in the depth of understand-
ing genome structure and function of living organisms, and in
the breadth of applications in areas, such as medicine (disease
mechanisms, diagnostics, and therapeutics) and agriculture (2, 3).
Using high-throughput DNA sequencing for pathogen detection
during an infectious disease outbreak or for biosurveillance was
previously slow, cost prohibitive, and required in-depth train-
ing and expertise. In the past decade, due to the advancement
of highly automated instrument platforms, streamlined opera-
tional procedures and protocols, available reagent kits, and data
analysis pipelines (4), NGS has been in effect democratized,
expanding from central sequencing laboratories to individual
institutions. As a result, genomics has become a highly desir-
able area that inspires broad international collaborations target-
ing diverse applications (5). Examples of global health security
related applications include infectious disease diagnosis, previ-
ously unknown pathogens identification, sample archive char-
acterization, and biosurveillance. Even though NGS technology
has made high-throughput DNA sequencing more accessible, the
existence of the automated instruments and streamlined proce-
dures cannot replace the in-depth knowledge and expertise to
use the instruments with high proficiency and accuracy; nor
can the analytic algorithms analyze the experimental outcomes
with precise interpretation.Without specialized training and tech-
nical expertise, these technology advancements cannot be fully
utilized.
In support of the overarching scientific engagement objec-
tives, the Genome Science Program at the Los Alamos National
Laboratory (LANL) has been leveraging our own capabilities to
provide support to a growing number of partner countries on
four continents in developingmolecular genomic-based pathogen
detection and characterization capabilities. We approach such
development by first understanding partner country needs and
gaps in building genomics and bioinformatics capacities. This
is followed by scientific and technical training, facility building,
and dissemination of pipelines and processes for microorganism
genotypic characterization. Continuous subject matter expertise
reachback support is provided to the collaborators. Our efforts
in these areas enable the education of the next generation of life
scientists in the partner countries, providing a robust foundation
in genomic science through didactic and practical instruction,
and the required technical infrastructure for genomics research
by integrating sequencing and analytic capabilities.
While these genomics capabilities are being developed, the
collaborators start engaging in scientific collaborations utilizing
NGS and other molecular techniques, such as real-time PCR and
immunoassays. By applying these methods and correlating the
findings,we aim to better understand emerging infectious diseases
within the partner countries that are of global concern. The collab-
oration efforts will not only benefit the host countries and regions
with state-of-the-art life science methods and technologies but
also build a trusted international network with a shared passion
in addressing global emerging infectious disease challenges. Such
networks provide the potential for sharing resources, which is
essential for approaching the One Health objective and reducing
health threats globally.
STRATEGY AND APPROACH
Our international genomics development and collaboration
efforts have been built upon prior engagement activities carried
out by other institutions and sponsored by various donors. We
initially sought collaborations with countries that have been part-
ners with our sponsors for several years, such as the Republic of
Georgia and the Kingdom of Jordan. Many of the collaborating
institutions already have well-established capabilities inmolecular
diagnostics and genetic analysis, and hold principle responsibili-
ties in public and veterinary health in their respective countries.
To effectively achieve the scientific engagement objectives, we
have developed a phased strategy for establishing genomics lab-
oratories in partner countries, followed by continuous technical
support and cooperative scientific research to address some of the
pressing public and veterinary health challenges.
Phased Approaches for Capability Building
Our phased approach for establishing genomics centers with part-
ner countries provides both the starting momentum to build a
capability and flexibility that is responsive to the evolution of tech-
nologies and business practices, which reduces risks in achieving
sustainability. The four phases can be summarized as: (1) scientific
engagement evaluation, (2) technical strategy and development
planning, (3) infrastructure and technical capability building, and
(4) instrument operation and bioinformatics training. One most
critical consideration throughout all phases is the sustainability
development. Depending on the existing capabilities and infras-
tructure readiness, we do not necessarily go through all phases
with any given partner institution.
The phased approach to engagement and sustainment is shown
in Figure 1.
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FIGURE 1 | Phased approach, for NGS-based scientific engagement development.
Phase I, Scientific Engagement Evaluation and
Requirement Analysis
In order to provide meaningful assistance to our partner coun-
tries and their particular institutions, it is essential to understand
host country public health challenges and requirements, and to
carefully consider what a genomics capability can accomplish to
address their specific challenges. We first work directly with host
nation scientists and leadership to understand existing capabilities
and expertise in pathogen detection and characterization, urgent
public and veterinary health issues, and to assess the technologies
and capabilities compatible with genomics and bioinformatics.
Essential areas of consideration include: host country objectives
in genomic science and technology, desired near- and long-term
outcomes, type and availability of samples to be processed, antic-
ipated throughput and turnaround, potential future resources,
anticipated implementation timeline, and a long-term sustainabil-
ity vision. Other assessment areas include the existing technical
expertise in laboratory operation and bioinformatics, laboratory
infrastructure, computational infrastructure, and administrative
skills. An initial development strategy is formulated based on a
requirement analysis for the engagement partner to achieve full
operational capability, including the approach to narrowing the
gaps between the desirable end goals and the current status of
these resources.
Direct interactions with prominent regional life scientists,
medical, public health, and agriculture professionals provide the
collaborators with unique opportunities to identify areas for
advancement that would significantly impact the science in the
region or in the country; this allows us to build trust for a
long-term collaborative relationship. The availability of advanced
genomic science capabilities meets the foundational need that
would impact almost all areas of the life sciences and presents
opportunities for technology and economic development. During
this phase, we start deliberating a long-term sustainability plan,
based on the initial observations and development objectives.
Phase II, Technical Strategy and
Development Planning
Once the requirements and objectives are defined, we begin for-
mulating the technology strategy and development plan for a
given institution to reach the target objectives. Planning includes
personnel professional development, infrastructure preparation,
NGS instrument acquisition, and initiating collaboration logistics
including sample transportation and information sharing pro-
cedures. A technical action plan is generated that provides a
framework of recommended protocols, workflows, and required
training. In addition, the action plan provides recommended
paths to address the gaps and challenges in the existing laboratory
equipment, facility, and computational resources. We also gen-
erate a training plan to outline the tasks required for laboratory
staff to obtain proficiency using specific operational protocols,
pipelines, and processes. This includes sample preparation and
management, instrument operation, sequence data analysis, and
initial interpretation for biological significance.
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During this phase, we also introduce fundamental princi-
ples and basic techniques of molecular- and genomic-based
approaches for pathogen and infectious disease detection and
characterization, and assist partner countries to further define
priorities and needs for enhancing these capabilities. Initial train-
ing in these topics is provided either at LANL and/or at the
partner site.
Phase III, Infrastructure and Technical Capability
Development
The engagement activities subsequently progress into preparation
of the NGS laboratory facility, acquisition of laboratory instru-
ments and computational equipment, dissemination of standard-
ized operational protocols, and technical training for proficiency
building. The engagement collaborators work closely to design
and configure appropriate laboratory space and bioinformatics
systems at the partner facility. In this phase, careful considera-
tion of local constraints, logistics, and experience available at the
engagement partner site are critical.
The steps in this phase include
1. Wet-lab and informatics hardware specification and laboratory
setup. The specification is based on the existing facility infras-
tructure, equipment, expertise and target goals. It includes wet-
lab operational protocols and bioinformatics systems required
to accomplish the development objectives. Laboratory equip-
ment required for various wet-lab processes, and informatics
hardware and software to process data and perform analysis
are specified and acquisition is initiated. In some cases, the
acquisition is handled by LANL, and in other cases by a third-
party integrating contractor. Laboratory setup is performed
by a combination of vendors, partner staff, and LANL staff.
Good laboratory practice (GLP) is used as a guiding principle
to ensure high quality experimental output,minimize potential
cross-contamination, and protect the laboratory personnel.
2. Deploy wet-lab processes. We work with engagement part-
ners to deploy standardized wet-lab protocols and processes.
Example protocols include DNA library preparation for bac-
terial isolate sequencing, RNA library preparation for viral
sample sequencing, targeted microbial sequencing protocols,
whole genome sequencing (WGS), and general IlluminaMiSeq
platform sequencing procedures. Implementation of GLP is
stressed during this phase, and training in GLP is delivered
throughout all relevant phases.
3. Deploy informatics pipelines. Informatics pipelines coordinated
with wet-lab protocols are provided to the partner facil-
ity. Examples include initial sequencing data quality con-
trol and reporting, data quality treatment, genomic assembly,
reference-based assembly, and metagenomic analysis.
Phase IV, Training on Instrument Operation and
Bioinformatics Processing
A strong foundation built through training is a vital component of
the entire engagement activity. The collaborators work closely to
coordinate training sessions in both the US and on-site in the host
country facility. The primary goal is to instill a strong foundation
in both scientific principles and operational processes during the
exchange. On-site training focuses on development and imple-
mentation of sample preparation, sequencing library generation,
genome sequencing, and sequencing data analysis procedures
in compliance with GLP regulations. Great attention is paid to
hands-on troubleshooting, and additional training is provided as
needed. Training in this phase is an avenue to disseminate best
biosafety and biosecurity practices.
Throughout the exchange and following period, the US scien-
tists monitor partner performance and provide feedback to the
sponsors and partner country scientists. Bioinformatics reachback
assistance is provided to support current mission and long-term
development of sustainable approaches. Assistance is also pro-
vided to the partners in the development and execution of research
projects that utilizes the capability. Updating or expanding proto-
cols and processes and providing new versions to the engagement
partners are a continuous practice.
Sustainability Development
The sustained utilization of the new genomics capability and
continued service to society is the ultimate goal for the genomics
centers being developed. To support sustainable development,
we assist the institutions in identifying research and operational
areas, such as training their fellow scientists and public health
practitioners, conducting hypothesis-driven research, and provid-
ing services to community. The basic research, applied research,
and operational areas that will benefit from advanced genomics
science are extremely broad, virtually in all life sciences and
related fields of practice. Priorities are identified based on research
activities, public health responsibilities, and perceived societal
significance. These priority areas include emerging or unknown
pathogenic microorganism identification, molecular epidemiol-
ogy, phylogenetic characterization of infectious agents, and infec-
tious disease surveillance. In addition, genomics-assisted design
and development of new diagnostic signatures and assays, and
their applications in veterinary and agricultural practices have
become important areas of engagement.
After deploying genomics technologies at a partner site and
delivering initial training, successful capability establishment at
the host site typically requires on going assistance. LANL pro-
vides reachback support to the engagement partners, by delivering
remote, near real-time technical advice on wet-lab, informatics,
and data analysis. Laboratory support includes advice on sample
preparation procedures and protocols, and recommendation of
specific reagents or kits to use. Informatics-focused reachback
support can be especially important for somepartners, as theymay
have limited existing informatics capability to draw on. Reachback
on data analysis is very common, and can usually be a point of col-
laboration, from sequencing data quality evaluation to interpret-
ing biological significance. Internet connectivity is very important
for these purposes, and can sometimes be the rate-limiting factor.
Scientists at partner institutions are regularly invited to attend
and contribute to the annual Sequencing, Finishing, and Anal-
ysis in the Future (SFAF) meetings that LANL has hosted for
the past decade [SFAF (6)]. This conference provides an oppor-
tunity for the engagement partners to gain up-to-date knowl-
edge on new techniques and technologies, and to present their
own research results. Since 2013, LANL has hosted annual NGS
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training workshop in Los Alamos for engagement partners. The
workshop includes principles of NGS and hands-on training in
both laboratory techniques and bioinformatics. These opportuni-
ties provide avenues to broaden expertise and our collaborations
with international partners.
RESULTS
We have successfully established genome centers with partner
institutions in four different countries: Republic of Georgia,
Kingdom of Jordan, Uganda, and Gabon, and developed exten-
sive genomic research collaboration with several other countries.
These genome centers are provided with a standardized sequenc-
ing platform, standard operating protocols and GLP training,
and bioinformatics analysis tools and associated computational
hardware.
Standardized Platforms and Processes
At LANL, we have extensive experience withmost NGS platforms.
During the past decade,we have acquired everymajorNGS instru-
ment to conduct scientific research and to provide sequencing
service and training to our collaborators. The Illumina MiSeq
instrument was selected as the sequencing platform of choice for
the international genomics engagement activities for its compact
physical size, accompanying reagent kits, standardized operation
procedures, high quality data output, and broad applications (4, 7).
We have developed and disseminated standardized protocols for
sample preparation, quality control, sequencing, and data man-
agement protocols. The standardized protocols require a few other
supporting laboratory instruments for DNA fragmentation, qual-
ity control, quantification of DNA fragments, and quantitative
PCR, which are also provided to our partner facilities. The general
process flow is summarized in Figure 2.
Standard computer software and hardware have also been
specified to simplify installation and ongoing support. For com-
putational resources, the CLC Genomics Workbench (Qiagen)
was selected from several commercial options as an analysis
and visualization tool. This software package provides an inte-
grated environment with most types of tools necessary for our
partners to analyze sequencing data generated by MiSeq. In-
house developed bioinformatics tools are also disseminated to
the partner laboratories. The LANL developed EDGE Bioinfor-
matics (8) is an analytic tool that integrates a selection of open
source tools accessed by a web-based interface. EDGE has been
deployed to several of our partner facilities and has proven to
be an easy-to-use tool for rapid analysis of NGS data, requir-
ing little specialized bioinformatics expertise. The computational
hardware provided to our partners is fully sufficient to process
sequencing data generated by the MiSeq platform at the part-
ner’s site. This approach to deploying and training on a reper-
toire of technology and equipment has enabled us to franchise
genomics centers with standardized procedures for our partners.
The training and support we can provide is greatly enabled by this
standardization.
FIGURE 2 | The standard NGS laboratory and bioinformatics pipeline setting deployed to the partner laboratories.
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Current Collaborations
Wehave successfully established genome centerswith four partner
institutions in Georgia, Jordan, Uganda, and Gabon (Figure 3).
These genome centers are provided with a standardized sequenc-
ing platform, standard operation and GLP protocols, and bioin-
formatics analysis tools and associated computational hardware.
We travel to each site and assist with setup and configuration
for laboratory equipment and computational resources. On-site
training for both laboratory and bioinformatics are also provided
during these visits. We typically guide the partners to perform
one or more sequencing runs on the newly provided equipment
while we are on-site. A brief description of each genome center
is provided in Section “Established Genome Centers” below. In
addition to establishing these genome centers, we provide training
and engage in collaborative research with other institutions that
either already have NGS capability or are on a path to acquire
it. This type of collaboration has taken place in nine different
countries (Figure 3), and allows the partners to broaden interna-
tional collaboration networks and to exercise and enhance local
capabilities. These collaborations bring together complementary
skill sets and resources, benefiting all participating parties and
paving a good path to improved global health.
Established Genome Centers
Republic of Georgia: Genomics Center at the National
Center for Disease Control and Public Health
The National Center for Disease Control and Public Health of
Georgia (NCDC) was originally established in 1937 as the Anti-
Plague Station, investigating species and the spread of Yersinia
pestis in Georgia. After a tularemia outbreak in Southern Georgia
in 1946, the institutional mission scope was expanded to include
the investigation of tularemia and subsequently other infectious
diseases, such as anthrax. The institution has since become the
leading epidemiological control organization in Georgia, and later
established the national reference laboratory now known as the R.
G. Lugar Center for Public Health Research in 2013.
The genome center at Georgian NCDC was established in
2012. Extensive training took place for the Georgian scientists at
both LANL and NCDC on NGS sample preparation protocols,
MiSeq operations, and bioinformatics analysis of sequencing data.
Reachback support in the form of teleconference calls, emails, and
remote logins has been delivered to the Georgians on a regular
basis. Today, the NCDC genome center is fully functional and
more than 10 staffs have been trained and are regularly using
the capabilities to conduct scientific research in pathogen viru-
lence characterization and biosurveillance for infectious diseases.
LANL and NCDC scientists have also embarked on joint research
projects utilizing the new NGS capability. An example of research
activities is highlighted in Section “Initial Cooperative Research
Highlights,” and a new project has been initiated as a result of a
competitive proposal process.
Kingdom of Jordan: Jordan University of Science and
Technology
The Princess Haya Biotechnology Center (PHBC) at the Jordan
University of Science and Technology (JUST) was established in
2005. The Center represents the state-of-the-art biotechnology in
clinical applications, supported by Princess Haya Bint Al Hus-
sein, with a primary responsibility directed toward supporting the
Jordanian medical and scientific communities. It is hosted at the
King Abdullah University Hospital and is equipped with modern
facilities for carrying out research, diagnostic laboratory testing
and training in areas of genomics, proteomics, metabolomics,
hematology, and other clinical areas.
In 2012, LANL initiated collaborations with the PHBC to
develop an NGS genomics capability. Applying the phased
approach detailed in Section “STRATEGY AND APPROACH,”
FIGURE 3 | Partner countries. Red marks indicate genome centers established by our program. Yellow marks countries that are in collaborations focusing on
training and research.
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a functional NGS facility for genomics research and train-
ing was established in early 2015. Leveraging our experience
with the Georgian project, we specified laboratory equipment
and computational resources to match the capability target,
level of PHBC staff expertise, and existing PHBC laboratory
resources. During 2013 through 2015, extensive training and
traveling took place for JUST staff to receive GLP, laboratory
protocols, and bioinformatics analysis trainings, at both LANL
and JUST. Currently, joint research projects are being planned
to exercise the genomics capability and further train JUST
staff.
Uganda: The Uganda Virus Research Institute
Uganda Virus Research Institute (UVRI) is a Ugandan national
reference laboratory for various viral diseases including hemor-
rhagic fevers, HIV, and Influenza. AnNGS capability based on the
MiSeq platform is being incorporated into laboratory operations
at UVRI, especially during epidemic outbreak investigations for
enhanced pathogen detection.
In August 2013, LANL staff traveled to Uganda for the initial
evaluation of UVRI facilities and expertise, the Phase I in our
overall approach. New construction at UVRI was beginning on
the space that would become the home of the genome center.
Recommendations on infrastructure details as a fully functional
genomics laboratory were quickly provided and implemented.
Detailed planning for the genome center development completed
in 2013. During 2014, facility construction was completed and
laboratory equipment was delivered. In October 2014, LANL
scientists traveled to Uganda to assist UVRI staff in setting up the
genome center and to deliver the first round of on-site training
to UVRI staff. LANL staff returned to UVRI in February 2015
to deliver additional training in laboratory protocols and bioin-
formatics analysis. During this visit, the genome center started
sequencing and analyzing several clinical samples of unknown
viral diseases.
Gabon: International Center for Medical Research in
Franceville
Los Alamos National Laboratory is working with a research insti-
tute in Gabon, the International Center for Medical Research
in Franceville (CIRMF) to enhance their genomics capabilities.
CIRMF was founded in 1979 to conduct research in fertil-
ity, immunology, pathology, and microbiology. Today, CIRMF
has refocused almost exclusively on infectious diseases with an
emphasis on microbiological monitoring and assistance to public
health. LANL is assisting the CIRMF to set up a genomics center
to achieve these objectives. In February 2015, LANL staff traveled
to Franceville to provide technical assistance to the facility and
staff, to assist in addressing technical challenges in operating a
newly acquired MiSeq, and to set up a new bioinformatics system
that we assisted CIRMF in acquiring. In this engagement, the early
evaluation and planning phases were unnecessary, as the CIRMF
was already in the process of developing a genomics capability.
An evaluation of the current state and the level of expertise
were performed and recommendations for additional equipment
and training were given. These recommendations are now being
implemented.
Initial Cooperative Research Highlights
Through these international partnerships, extensive collaboration
planning and executions are being carried out. After 2–3 years
of collaboration, research efforts have started producing initial
results at various centers. A few examples are listed below:
CRISPR Analysis of Yersinia pestis Strains from
Georgia
Three Y. pestis strains isolated from two historical natural plague
sites of Georgia were analyzed based on their CRISPR (Clustered
Regularly Interspaced Short Palindromic Repeats) features. In the
Y. pestis genome, three CRISPR elements YPa, YPb, and YPc are
found at three distinct loci and presently 137 spacer sequences are
known (9). These CRISPR elements are highly correlated with the
region and location of isolation, potentially providing important
genotyping and evolutionary information, which could help to
trace the source of outbreaks. TheMiSeq platform at the Georgian
NCDC Lugar Center was used to conduct WGS of the isolates.
The Georgian scientists have gained sufficient analytical skills
through training, and successfully applied the two bioinformatic
pipelines that have been deployed (CLCBioGenomicsWorkbench
and EDGE Bioinformatics) to perform the analysis.
MERS-CoV Patient Sample Analysis
In 2013, an outbreak of MERS-CoV occurred in the Middle East,
including Jordan (10, 11). Two individuals with severe respiratory
symptoms were suspected of having been infected by the virus
were admitted to the King Abdullah University Hospital; the
throat swabs were sent to PHBC for analysis. One of the patients
did not survive after hospital admission. Total RNAwas isolated by
PHBC staff, and samples were sequenced with theMiSeq platform
and supplemented with additional Illumina HiSeq sequencing.
The presence of MERS-CoV virus was confirmed in both samples
usingNGS. Even though the samples were degraded, the virus was
present in sufficient abundance for us to obtain the entire viral
genome from one of the samples, revealing that it was related to
the original outbreak in Saudi Arabia. This type of high-resolution
analysis of clinical samples can now be achieved at JUST by the
trained local scientists and laboratory staff. It will enable faster
detection and more detailed tracking of future outbreaks, and
reach further research objectives.
RNA Virus Sequencing and Analysis at the
UVRI Genome Center
After two rounds of training, the UVRI staff analyzed several
blood samples from patients presenting with various viral hemor-
rhagic fever (VHF) symptoms. RNA was extracted and converted
to sequencing libraries for sequencing on the UVRIMiSeq instru-
ment. The URVI scientists applied the standardized protocols
received during the laboratory setup and training session to per-
form an initial quality control check, quantification, RNA sample
preparation, and concentration measurement. Sequencing library
preparation, validation, and quantification were performed using
standard protocols provided by LANL, and NGS was performed
on the UVRI MiSeq. The Ugandan scientists successfully applied
the two bioinformatic pipelines that have been deployed (CLCBio
Genomics Workbench and EDGE Bioinformatics) to perform the
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sequencing data analysis. While no hemorrhagic fever viruses
were present in the samples, the analyses revealed some potential
bacterial pathogens that may have caused the symptoms.
Our collaboration partners continue to actively explore the
application of NGS to their local needs. Research ideas include
the characterization of samples from long-term archives. This
would include the application of NGS to the investigation of
past unexplained illnesses, characterization of pathogens from
geographical areas across different time periods, and possibly the
identification of previously unknown pathogens to the local area.
Studying the zoonotic diseases endemic to the partner countries
is also of high interest. Andmany partners are interested in devel-
oping a quality reference database of pathogen strains within their
purview. Application to clinical, animal, and agricultural samples
is a common theme.
CONCLUSION
Our experience in collaborating with our international partners
has been very fruitful and rewarding.Wehave successfully assisted
in the development of genome centers in four countries: Republic
of Georgia, Kingdom of Jordan, Uganda, andGabon.We have also
established long-term partnerships with genomic laboratories in
many other countries. Enthusiasm for utilizingNGS at each center
continues to build, and several projects have begun. These early
projects aim to detect and characterize pathogens from clinical,
animal, or environmental samples.
These collaborative experiences have not gone without certain
challenges. Some of the challenges have been of a logistical nature,
such as acquiring reagents in a timely fashion, which is critical
to the success of the research and training. On more than one
occasion after reagents were ordered, the items were delivered
after the manufacturer listed expiration date due to logistical
delays. Proper infrastructure support is another main challenge
for NGS capability, including environmental heating, cooling and
ventilation. Stable and clean electrical power is very important
and not always present. Reliable and efficient Internet access is
required for NGS operation; Internet access is improving rapidly
in all partner locations, but remains a point of concern.
Partner staff expertise and proficiency building is key to the
success of these collaborations.Most scientists and technicians are
experienced biologists but lack bioinformatics expertise. Train-
ing a biologist in the techniques of genome science is relatively
straightforward but achieving informatics proficiency requires
a basic starting level which is lacking. The partner countries
typically do not have ready access to bioinformatics skills, and this
continues to be a challenge. Our recent deployment of the EDGE
bioinformatics tool has been an attempt to overcome this chal-
lenge, which was designed for general users without specialized
bioinformatics training.
Sustainment of the genome science capabilities with our part-
ners is a key concern. We continue to improve the expertise of
these partners through training and scientific conference oppor-
tunities. Sustainable use of the established NGS technologies will
be strengthened by performing regular research projects. These
research projects will be funded by international sponsors, and
will provide funds for reagents and research time by partner staff.
Over time, this approach will enable the partners to exercise and
develop genomic capabilities and continue on a path to sustain-
ability. A recently funded research project with NCDC in Georgia
resulted from a competitive proposal process is a positive example.
Development of genome centers in many countries around
the World will not only help the local public health authorities
identify and monitor disease outbreaks but will also enable true
global biosurveillance at a high temporal, geographic, and infor-
mation resolution (12–14). Considering the potential for the rapid
spread of the known pandemic pathogens and future emerging
ones, a network of genome centers that can rapidly provide high-
resolution genomic data will help improve the speed and accuracy
of outbreak detection and monitoring, and reduce the global
threat from these pathogens. The speed and efficacy of mitigation
will be largely increased by the ability to test the samples locally,
without having to ship the sample long distances. This approach
offers a large safety benefit, as clinical samples containing live
pathogens do not have to be moved long distances or across bor-
ders, and potentially cause additional outbreaks. Successful scien-
tific partnerships and sustainable technical capacity are essential
to addressing complex global health security challenges to realize
the One Health concept.
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